Koleva M, Donchev N, Udvareva N, Dzharova V
Eksp Med Morfol. 1990;29(4):52-7.
Results from the study on acute, subacute and chronic toxicity of the therapeutic preparation pharmapentoxiphyline (PP), produced by Pharmachem, are described. The experiments were carried out on 312 male and female white rats. According to the limiting index of LD50 with, Oral dose of (1220 mg/kg of body mass for male rats and 1050 mg/kg for female rats) and intraperitoneal PP dose of PP (230 mg/kg for female rats and 235 mg/kg for female rats) it was included into IV class of slightly toxic compounds. Doses of 100, 300 and 600 mg/kg/oral administration) and 30, 75 and 150 mg/kg (intraperitoneal administration) were used in subacute and chronic experiments. Integral, hematological and biochemical methods and parameters were applied for evaluation of the toxic effect. There was no hemato-, hepato- and nephrotoxicity after oral and intraperitoneal administration of PP in doses of 10 and 30 mg/kg for a period of 3 months. Some recommendations, which should be taken into consideration during continuous treatment with PP, are given on the basis of a complex evaluation of the results from the hematological parameters.
描述了对Pharmachem生产的治疗制剂戊氧苯茶碱（PP）进行的急性、亚急性和慢性毒性研究结果。实验在312只雄性和雌性白色大鼠身上进行。根据半数致死剂量（LD50）的极限指数，口服剂量（雄性大鼠为1220毫克/千克体重，雌性大鼠为1050毫克/千克）和腹腔注射PP剂量（雌性大鼠为230毫克/千克，雌性大鼠为235毫克/千克），它被归入微毒化合物IV类。在亚急性和慢性实验中使用了100、300和600毫克/千克（口服给药）以及30、75和150毫克/千克（腹腔注射给药）的剂量。采用综合、血液学和生物化学方法及参数来评估毒性作用。在为期3个月的时间里，以10和30毫克/千克的剂量口服和腹腔注射PP后，未出现血液、肝脏和肾脏毒性。基于对血液学参数结果的综合评估，给出了在持续使用PP治疗期间应考虑的一些建议。
